Potencyevaluation of a formulated drug product containing 150-kd botulinum neurotoxin type a

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 28-31

  Hunt, Terrence ^a   Clarke, Kenneth ^a  

^a ALLERGAN INC   (United States)

Author keywords

150kD; 900kD; BOTOX; Botulinum toxin type A; Drug product; Potency; Stability; Xeomin

Indexed keywords

BOTULINUM TOXIN A; NEUROTOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG QUALITY; DRUG STABILITY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL TESTING ALTERNATIVE; CHEMISTRY; DOSE RESPONSE; EVALUATION; FOLLOW UP; MOLECULAR WEIGHT; SURVIVAL;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; MICE; MOLECULAR WEIGHT; NEUROTOXINS; SURVIVAL ANALYSIS;

EID: 67749120071     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181692735     Document Type: Article

References (16)

1. Sakaguchi G, Kozaki S, Ohishi I. Structure and function of botulinum toxins. In: Alouf JE, ed. Bacterial Protein Toxins. London: Academic Press; 1984:435-443.
2. Hatheway CL. Bacterial sources of clostridial neurotoxins. In: Simpson LL, ed. Botulinum Neurotoxin and Tetanus Toxin. San Diego: Academic Press; 1989:30-24.
3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87: 1044-1049.
4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103: 347-350.
5. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-247.
6. Schantz EJ, Kautter DA. Microbiological methods: standardized assay for clostridium botulinum toxins. J Assoc Off Anal Chem 1978;61:96-99.
7. Pearce LB, Borodic GE, Johnson EA, et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 1995;33:217-227.
8. McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-985.
9. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-1451.
10. Roggenkämper P, Jost WH, Bihari K, et al. for the NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Trans 2006;113:303-312.
11. European Pharmacopoeia. 5th ed. Botulinum Toxin Type A for Injection. Monograph January 2005:2113.
12. Zbinden G, Flury-Roversi M. Significance of the LD50-test for the toxicological evaluation of chemical substances. Arch Toxicol 1981;47:77-99.
13. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.
14. Chen F, Kuziemko GM, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 1998;66:2420-2425.
15. Sharma SK, Singh BR. Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. J Nat Toxins 1998;7(3):239-253.
16. BOTOX (Botulinum Toxin Type A). Purified Neurotoxin Complex [package insert]. Ireland: Allergan Pharmaceuticals Ltd; 2004.